Simcha Therapeutics Announces First Patient Dosed in Phase 1/2 Study Evaluating ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors

Simcha Therapeutics, a clinical-stage immunobiology company, has announced that the first patient has been dosed in a Phase 1/2 clinical trial of ST-067 in combination with Merck's anti-PD-1 therapy, KEYTRUDA®, for patients with advanced solid tumors. The study aims to determine the maximum tolerated dose and preliminary activity of the combination treatment. Simcha Therapeutics has observed pro..